

# Gontran Verset

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8096888/publications.pdf>

Version: 2024-02-01

14  
papers

2,035  
citations

1040056

9  
h-index

1058476

14  
g-index

14  
all docs

14  
docs citations

14  
times ranked

3175  
citing authors

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 1  | Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib. <i>European Journal of Cancer</i> , 2022, 167, 1-12.   | 2.8  | 43        |
| 2  | Systemic Treatments with Tyrosine Kinase Inhibitor and Platinum-Based Chemotherapy in Patients with Unresectable or Metastatic Hepatocholangiocarcinoma. <i>Liver Cancer</i> , 2022, 11, 460-473.  | 7.7  | 13        |
| 3  | Balloon-occluded chemoembolization for hepatocellular carcinoma: a prospective study of safety, feasibility and outcomes. <i>Hepatic Oncology</i> , 2021, 8, HEP31.  | 4.2  | 4         |
| 4  | Retrospective European Multicentric Evaluation of Selective Transarterial Chemoembolisation with and without Balloon-Occlusion in Patients with Hepatocellular Carcinoma: A Propensity Score Matched Analysis. <i>CardioVascular and Interventional Radiology</i> , 2021, 44, 1048-1059. | 2.0  | 14        |
| 5  | Unusual metastasis in BRCA mutated pancreatic cancer while on maintenance Olaparib: Two case reports and review of the literature. <i>European Journal of Cancer</i> , 2021, 157, 63-67.   | 2.8  | 2         |
| 6  | Balloon-Occluded Transarterial Chemoembolization: In Which Size Range Does It Perform Best? A Comparison of Its Efficacy versus Conventional Transarterial Chemoembolization, Using Propensity Score Matching. <i>Liver Cancer</i> , 2021, 10, 522-534.                                  | 7.7  | 10        |
| 7  | In the Era of Systemic Therapy for Hepatocellular Carcinoma Is Transarterial Chemoembolization Still a Card to Play?. <i>Cancers</i> , 2021, 13, 5129.   | 3.7  | 2         |
| 8  | Real Life Prospective Evaluation of New Drug-Eluting Platform for Chemoembolization of Patients with Hepatocellular Carcinoma: PARIS Registry. <i>Cancers</i> , 2020, 12, 3405.  | 3.7  | 10        |
| 9  | Retrospective analysis of the immunogenic effects of intra-arterial locoregional therapies in hepatocellular carcinoma: a rationale for combining selective internal radiation therapy (SIRT) and immunotherapy. <i>BMC Cancer</i> , 2020, 20, 135.                                      | 2.6  | 32        |
| 10 | Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. <i>Lancet Oncology</i> , The, 2018, 19, 940-952.   | 10.7 | 1,816     |
| 11 | Pembrolizumab (pembro) in patients with advanced hepatocellular carcinoma (HCC): KEYNOTE-224 update.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4020-4020.   | 1.6  | 9         |
| 12 | KEYNOTE-224: Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib.. <i>Journal of Clinical Oncology</i> , 2018, 36, 209-209.   | 1.6  | 30        |
| 13 | Personalized medicine in pancreatic cancer: the revolution has begun. <i>Personalized Medicine</i> , 2015, 12, 515-523.  | 1.5  | 1         |
| 14 | Gastrointestinal polypoid lesions: a poorly known endoscopic feature of portal hypertension. <i>United European Gastroenterology Journal</i> , 2014, 2, 189-196.   | 3.8  | 49        |